Develops plasma-derived protein therapeutics for rare diseases and specific medical conditions, focusing on improving patient outcomes through biopharmaceutical innovations.
Kamada Ltd. specializes in the development and distribution of plasma-derived protein therapeutics, operating across two distinct segments: Proprietary Products and Distribution. The company's diverse portfolio includes a range of therapeutic solutions aimed at addressing critical medical conditions.
Among its notable offerings, Kamada provides KAMRAB/KEDRAB for rabies prophylaxis, CYTOGAM for cytomegalovirus prevention post-transplantation, and WINRHO SDF for immune thrombocytopenic purpura. Additionally, its product lineup features HEPAGAM B for hepatitis B prevention in liver transplant patients, VARIZIG for varicella post-exposure prophylaxis, and GLASSIA for alpha-1 antitrypsin deficiency treatment. Kamada also supplies KamRho (D) for hemolytic disease of newborns and snake bite antiserum for vipera palaestinae and echis coloratus bites.
Operating globally, Kamada leverages strategic partnerships with industry leaders such as Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma to enhance its market reach and distribution capabilities. The company, founded in 1990 and headquartered in Rehovot, Israel, continues to expand its portfolio through innovative research and development efforts aimed at meeting the evolving needs of patients worldwide.
With a commitment to advancing healthcare solutions, Kamada remains dedicated to improving treatment options across a spectrum of diseases and conditions, ensuring its products contribute to better patient outcomes and quality of life globally.